Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Vornorexant (TS-142) in Patients with Hepatic Impairment
NCT05624944Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vornorexant in Insomnia (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Plasma concentration of TS-142 and Pharmacokinetic parameters. Started Dec 2022; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05624944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624944.